Humana (NYSE:HUM) Issues FY 2026 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 9.000-9.000 for the period, compared to the consensus earnings per share estimate of 12.030. The company issued revenue guidance of -.

Humana Price Performance

NYSE:HUM opened at $178.99 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.00. The company has a 50-day moving average of $246.13 and a 200-day moving average of $261.18. Humana has a 52 week low of $169.61 and a 52 week high of $315.35. The company has a market capitalization of $21.53 billion, a price-to-earnings ratio of 18.23, a PEG ratio of 1.95 and a beta of 0.44.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.01) by $0.05. The firm had revenue of $32.64 billion during the quarter, compared to analyst estimates of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The company’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, equities research analysts anticipate that Humana will post 16.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on HUM shares. Raymond James Financial set a $201.00 price target on Humana in a research note on Thursday. Robert W. Baird reduced their target price on shares of Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a research note on Thursday, December 11th. The Goldman Sachs Group dropped their target price on shares of Humana from $235.00 to $215.00 and set a “sell” rating for the company in a research report on Monday, November 24th. Jefferies Financial Group cut their price target on shares of Humana from $310.00 to $235.00 and set a “buy” rating for the company in a report on Thursday. Finally, Leerink Partners decreased their price objective on shares of Humana from $267.00 to $185.00 and set a “market perform” rating on the stock in a research note on Thursday. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $248.64.

Key Headlines Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Q4 results marginally beat expectations: Humana reported EPS of ($3.96) vs. consensus ($4.01) and revenue of $32.64B, with revenue up ~11% year/year — evidence the business still has top‑line momentum. Humana Reports Fourth Quarter 2025 Financial Results
• Positive Sentiment: Medicare Advantage membership is growing fast and CenterWell continued to drive revenue — management flagged a ~25% MA membership increase for 2026, which supports medium‑term growth expectations even as margins recover. Humana outlines 25% Medicare Advantage membership growth
• Neutral Sentiment: Some analysts remain constructive or neutral after the print — Jefferies kept a Buy stance while lowering its target to $235 (still well above the current price), creating a counterbalance to the downgrades. Jefferies lowers price target to $235
• Neutral Sentiment: TD Cowen maintained a Hold with a $173 target, signaling cautious tone from some Street strategists even as views diverge. TD Cowen Hold rating
• Negative Sentiment: FY‑2026 guidance was cut materially: Humana set EPS guidance of 9.00 vs. the Street ~12.03, citing lower quality Star Ratings and margin pressure — the guidance shortfall is the principal driver of the recent selloff and investor concern. Humana forecasts 2026 profit below estimates (Reuters)
• Negative Sentiment: Q4 GAAP loss widened and margins are under stress from rising MA medical costs and Star Ratings pressure — investors are focused on near‑term profitability risk even as membership rises. Humana Reports $796 Million Loss (Forbes)
• Negative Sentiment: Multiple firms cut price targets and slashed forecasts after the results and outlook — Evercore, Leerink, Cantor and others trimmed targets (some now near or below the stock), increasing downside risk from analyst revisions. Analysts slash forecasts after Q4 (Benzinga)
• Negative Sentiment: Shares recently hit a 52‑week low after the weak outlook; today’s uptick appears to be a short‑term rebound as investors parse the offset between growth and profit risk. Humana hits 52-week low (Benzinga)

Institutional Trading of Humana

Institutional investors and hedge funds have recently made changes to their positions in the business. Revolve Wealth Partners LLC bought a new stake in shares of Humana in the 4th quarter valued at $202,000. Sivia Capital Partners LLC raised its position in Humana by 53.7% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock valued at $316,000 after buying an additional 452 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Humana in the second quarter valued at approximately $312,000. Teza Capital Management LLC grew its position in Humana by 9.4% in the second quarter. Teza Capital Management LLC now owns 1,255 shares of the insurance provider’s stock valued at $307,000 after purchasing an additional 108 shares in the last quarter. Finally, Certuity LLC acquired a new stake in shares of Humana in the third quarter valued at about $256,000. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.